We recently compiled a list of the 10 High Growth Pharma Stocks That Are Profitable in 2025. Zoetis Inc. is one of them.
Zoetis Inc. (NYSE:ZTS), a New Jersey–based global leader in animal health, continues to strengthen its position in the industry with medicines and vaccines for both companion animals and livestock. The company is particularly recognized for its innovations in parasiticides, dermatology, and vaccines that enhance animal well-being.
In its second-quarter 2025 earnings report, Zoetis Inc. (NYSE:ZTS) delivered stronger-than-expected results, posting $2.5 billion in revenue, an 8% increase driven by both volume and price growth. Building on this momentum, the company raised its full-year revenue outlook to between $9.45 billion and $9.60 billion, underscoring confidence in sustained demand across key markets and reinforcing its standing among high growth stocks in the animal health sector.
Growth was fueled largely by the continued success of Simparica Trio, a leading flea, tick, and heartworm treatment for pets, as well as strong performance in dermatology products, including Apoquel, Solens, and Cytopoint. The livestock segment also showed signs of recovery, though it faced competitive pressures and supply challenges.
CEO Kristin Peck emphasized Zoetis Inc. (NYSE:ZTS)’ resilience amid macroeconomic headwinds, crediting disciplined execution and a sharp focus on innovation. She also highlighted the corporation’s opportunities for expansion, citing recent product approvals and label extensions across global markets such as Japan, Australia, Brazil, and the EU.
While we acknowledge the potential of ZTS as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.
Disclosure. None.